Galapagos and Adaptimmune Announce Clinical Collaboration Agreement for TCR T-cell Therapy in Head & Neck Cancer

Thursday, 30 May 2024, 17:12

The post details the collaboration between Galapagos and Adaptimmune for the development of uza-cel therapy in head & neck cancer. This clinical agreement includes an option for Galapagos to exclusively license Adaptimmune's TCR T-cell therapy candidate, presenting significant potential for the future of cancer treatment.

https://store.livarava.com/02cade51-1ec2-11ef-a3ea-9d5fa15a64d8.jpg — Galapagos and Adaptimmune Announce Clinical Collaboration Agreement for TCR T-cell Therapy in Head & Neck Cancer

Galapagos and Adaptimmune Clinical Collaboration

In a strategic move, Galapagos and Adaptimmune have agreed to collaborate on the development of uza-cel therapy for head & neck cancer.

Exclusive Licensing Option

Adaptimmune's TCR T-cell therapy candidate uza-cel holds promise for future cancer treatments, leading to an exclusive licensing option for Galapagos.

Significant implications for the future of cancer therapy
Potential breakthrough in head & neck cancer treatments

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.